Onset of Musculoskeletal Adverse Events Varies Between Statins

MONDAY, Nov. 19, 2018 -- The onset of musculoskeletal adverse events (MAEs) during statin monotherapy is significantly faster with use of atorvastatin and rosuvastatin versus simvastatin, according to a study published online Nov. 7 in Pharmacology...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Nat. Prod. Rep., 2019,36,698-713 DOI: 10.1039/C8NP00075A, Review ArticleCooper S. Jamieson, Masao Ohashi, Fang Liu, Yi Tang, K. N. Houk The pericyclases are Nature's route to spirotetronates, statins, myceliothermophins, leporins and more. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Nat. Prod. Rep. latest articles - Category: Chemistry Authors: Source Type: research
Authors: Faggiano P, Fattirolli F, Frisinghelli A, Piccioli L, Dasseni N, Silverii MV, Albricci L, D'Ambrosio G, Garrì R, Esposito L, Giallauria F Abstract The present study aims at evaluating the achievement of blood pressure, lipid and blood glucose targets, healthy lifestyle changes and appropriate drug prescription/adherence in patients attending secondary prevention/CR ambulatory visit after index cardiovascular event in a time period ranging 1 to 5 year. At ambulatory visit, a predetermined set of data collection was used, including demographic data, cardiovascular risk factors and lifestyle habits, ty...
Source: Monaldi Archives for Chest Disease - Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research
Publication date: Available online 22 May 2019Source: American Heart JournalAuthor(s): Michael G. Nanna, Ann Marie Navar, Tracy Y. Wang, Shuang Li, Salim S. Virani, Zhuokai Li, Jennifer G. Robinson, Veronique L. Roger, Peter W.F. Wilson, Anne C. Goldberg, Andrew Koren, Michael J. Louie, Eric D. PetersonAbstractBackgroundAdherence to guideline-recommended statin recommendations in the United States (U.S.) is suboptimal. Patients' likelihood to be treated according to guidelines may vary by the practice in which they are treated.MethodsVariation in the use of statin therapy in 5445 patients, with known or at high risk for at...
Source: American Heart Journal - Category: Cardiology Source Type: research
This study determine the relative treatment effects of NST on fatal and nonfatal CV events among statin-treated patients. Methods A network meta-analysis based on a systematic review of randomized controlled trials (RCTs) comparing non-statin lipid-modifying agents among statin-treated patients was performed. PubMed, EMBASE, CENTRAL, and Clinicaltrial.gov were searched up to April 10, 2018. The primary outcomes were CV and all-cause mortalities. Secondary CV outcomes were coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), any stroke, and coronary revascularization. Risks of discontinuations were ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Atherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVD), is a lipid-driven, inflammatory disease of the large arteries. Gold standard therapy with statins and the more recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have improved health conditions among CVD patients by lowering low density lipoprotein (LDL) cholesterol. Nevertheless, a substantial part of these patients is still suffering and it seems that ‘just’ lipid lowering is insufficient. The results of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) have now proven tha...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
AbstractOlder adults with chronic kidney disease (CKD) often receive treatment with multiple medications and are vulnerable to adverse treatment-related outcomes. Although specific guidelines for deprescribing (defined as the process of eliminating or reducing the use of unnecessary and/or inappropriate medications) in older patients with CKD are lacking, a systemic process should be used to assess the individual patient, identify the use of potentially inappropriate medications (PIMs), and deprescribe such medications when possible. Dosage tapering is needed when some commonly used PIMs (e.g. proton pump inhibitors and or...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
In conclusion, the results of the present study reveal the possible molecular mechanism of simvastatin-induced anti-tumor effects in C666-1 and suggest that simvastatin is a potential chemotherapy agent in NPC treatment. PMID: 31105786 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
CONCLUSION: Statins can prevent the proliferative HCB effects on Hep-G2 cells. TGF-βΙ, c-Src and TH may be the statins molecular targets in hepatocarcinogenesis. PMID: 31103154 [PubMed - in process]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
CONCLUSIONS: In a "real-life" general population, the association between vitamin D deficiency and unexplained elevated ALT is specific for non-obese men. The clinical significance of vitamin D for human NAFLD should be further elucidated with attention for a modifying effect of gender and adiposity. PMID: 31103458 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
In recent years, researchers have discovered a number of human gene variants or mutations that significantly lower blood cholesterol, and this also the risk of heart disease, such as DSCAML1, ANGPTL4, and ASGR1. Why does this work? Oxidized cholesterol contributes to the development of atherosclerosis with advancing age, by causing macrophages to falter in their work of removing cholesterol from blood vessel walls, become inflammatory, transform into foam cells, and die, leaving debris that grows the lesions the cells are trying to repair. Reducing overall cholesterol works because it reduces oxidized cholesterol as well. ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
More News: Atorvastatin Calcium | Cholesterol | Crestor | Drugs & Pharmacology | Lipitor | Pharmaceuticals | Rosuvastatin | Simvastatin | Statin Therapy | Study | Zivast | Zocor